Biocon
在场
是其中之一......
Biocon 是一家在股票代码 BIOCON (IN) 下上市的公司。
Biocon 在 2 个国家有直接业务。Biocon 拥有 3家子公司，其中包括 Bicara Therapeutics、Biocon Biologics 和 Syngene。
他们在：
高管
查看带有其 81 名主要高管的组织结构图
Biocon 搜索最多的简介
- Peter Bains, Group Chief Executive Officer
- Kiran Shaw, Chairman & Managing Director
- Ravi Mazumdar, Non-Executive Director
高管在Biocon变化
- Mukesh Kamath 曾任 Head, Business Finance R&D, 现升职为 Interim Chief Financial Officer (新闻发布的2024六月11号).
创建提醒
跟踪 Biocon 的高管变动
药店
Biocon 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Biocon 的最新新闻稿
- Biocon Press Releases 2019
- Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
- Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167%
- Biocon Media - Press Release 2017
- Biocon Press Releases 2019
- Biocon Media - Company Statement on Biocon's Generic Formulations Facility in Bengaluru Completes U.S. FDA Inspection with No 483 observations
- Biocon Media - Press Release 2017
- Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167%
- Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
- Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
- View more press releases Close
通过电子邮件
